RhumbLine Advisers’s Acumen Pharmaceuticals ABOS Stock Holding History

RhumbLine Advisers’s Portfolio ABOS Stock Details ABOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$93.5K	Buy	+35,034	New	+$86.5K	﹤0.01%	3554
2025 Q2	–	Sell	-45,516	Closed	-$50.1K	–	4139
2025 Q1	$50.1K	Sell	45,516 -7,560	-14%	-$10.8K	﹤0.01%	3576
2024 Q4	$91.3K	Sell	53,076 -35,408	-40%	-$85.3K	﹤0.01%	3502
2024 Q3	$219K	Buy	88,484 +36,161	+69%	+$98.1K	﹤0.01%	3191
2024 Q2	$127K	Buy	+52,323	New	+$167K	﹤0.01%	3438
2022 Q2	–	Sell	-20,273	Closed	-$79K	–	3085
2022 Q1	$79K	Buy	+20,273	New	+$110K	﹤0.01%	2930

Other funds holding ABOS

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

SCV

Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

KIA

Knollwood Investment Advisory Hunt Valley, Maryland $1.12B AUM 41.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

RhumbLine Advisers's ABOS Position: Q2 2026 in Review

RhumbLine Advisers opened a new position in Acumen Pharmaceuticals (ABOS) in Q2 2026: 35,034 shares worth $93.5K. The stake represents ﹤0.01% of the portfolio and ranks #3554 among its holdings. This is a return to the name: RhumbLine Advisers previously reported a position in ABOS as recently as Q1 2025.

RhumbLine Advisers first reported a position in ABOS in Q1 2022 and has held it in 6 quarters since. The position peaked at $219K in Q3 2024. 96 funds tracked by Wall St. Rank hold ABOS as of Q2 2026.

RhumbLine Advisers held 35,034 shares of Acumen Pharmaceuticals worth $93.5K as of Q2 2026.
Acumen Pharmaceuticals was a new RhumbLine Advisers position in Q2 2026.
Acumen Pharmaceuticals made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #3554 holding.
RhumbLine Advisers first reported a position in Acumen Pharmaceuticals in Q1 2022 and has held it in 6 quarters since.
RhumbLine Advisers's Acumen Pharmaceuticals position peaked at $219K in Q3 2024.
96 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.